COVID-19 prevention and multiple sclerosis management: The SAFE pathway for the post-peak.
COVID
DMT
Multiple sclerosis
Serological
Swab
Journal
Multiple sclerosis and related disorders
ISSN: 2211-0356
Titre abrégé: Mult Scler Relat Disord
Pays: Netherlands
ID NLM: 101580247
Informations de publication
Date de publication:
Sep 2020
Sep 2020
Historique:
received:
25
05
2020
revised:
30
05
2020
accepted:
08
06
2020
pubmed:
20
6
2020
medline:
22
12
2020
entrez:
20
6
2020
Statut:
ppublish
Résumé
We hereby report on our experience from Naples (South Italy), where the peak of coronavirus disease 2019 (COVID-19) has already passed. Assuming that COVID-19 will be circulating until vaccination and/or herd immunity is achieved (possibly not earlier than 2021), we have developed a protocol for the long-term management of multiple sclerosis (MS). We have defined a pathway for the access to the MS Centre with logistic, preventative and clinical recommendations, and have also included 14-day self-isolation and COVID-19 testing before some disease modifying treatments. Overall, we believe our experience could be helpful for MS management in the upcoming months.
Sections du résumé
BACKGROUND
BACKGROUND
We hereby report on our experience from Naples (South Italy), where the peak of coronavirus disease 2019 (COVID-19) has already passed.
METHODS
METHODS
Assuming that COVID-19 will be circulating until vaccination and/or herd immunity is achieved (possibly not earlier than 2021), we have developed a protocol for the long-term management of multiple sclerosis (MS).
RESULTS
RESULTS
We have defined a pathway for the access to the MS Centre with logistic, preventative and clinical recommendations, and have also included 14-day self-isolation and COVID-19 testing before some disease modifying treatments.
DISCUSSION
CONCLUSIONS
Overall, we believe our experience could be helpful for MS management in the upcoming months.
Identifiants
pubmed: 32554288
pii: S2211-0348(20)30358-8
doi: 10.1016/j.msard.2020.102282
pmc: PMC7283048
pii:
doi:
Types de publication
Letter
Langues
eng
Sous-ensembles de citation
IM
Pagination
102282Informations de copyright
Copyright © 2020 Elsevier B.V. All rights reserved.
Références
Neurology. 2020 Jun 2;94(22):949-952
pubmed: 32241953
Neurol Neuroimmunol Neuroinflamm. 2020 May 15;7(4):
pubmed: 32414755
Eur J Neurol. 2020 Sep;27(9):e50-e51
pubmed: 32402100
N Engl J Med. 2020 May 28;382(22):2158-2160
pubmed: 32329972
Neurotherapeutics. 2020 Jan;17(1):200-207
pubmed: 31452081
Mult Scler Relat Disord. 2020 Jul;42:102192
pubmed: 32570202
Neurology. 2017 Aug 8;89(6):555-562
pubmed: 28687718
Ann Neurol. 2020 Jun;87(6):794-797
pubmed: 32383812
J Med Virol. 2020 Sep;92(9):1518-1524
pubmed: 32104917
Neurology. 2020 May 19;94(20):886-891
pubmed: 32253352
J Neurol Neurosurg Psychiatry. 2018 Oct;89(10):1050-1056
pubmed: 29602795
Lancet Neurol. 2020 Jun;19(6):481-482
pubmed: 32359409
Int J Environ Res Public Health. 2020 May 13;17(10):
pubmed: 32414017
Open Forum Infect Dis. 2019 Oct 21;6(11):ofz445
pubmed: 31723572
Neurol Sci. 2020 Jun;41(6):1369-1371
pubmed: 32440979
Infect Dis Ther. 2020 Apr 8;:1-13
pubmed: 32292686
Emerg Microbes Infect. 2020 Dec;9(1):747-756
pubmed: 32196430
Mult Scler Relat Disord. 2020 Jul;42:102185
pubmed: 32408147
JAMA Neurol. 2020 Feb 1;77(2):184-191
pubmed: 31589278
Science. 2020 Apr 3;368(6486):14-16
pubmed: 32241928